BM 15766

7-dehydrocholesterol reductase antagonist

Also Known As:

4-(2-(1-(4-chlorocinnamyl)piperazin-4-yl)ethyl)benzoic acid; BM-15.766; BM-15766; BM15.766; Benzoic acid, 4-(2-(4-(3-(4-chlorophenyl)-2-propenyl)-1-piperazinyl)ethyl)-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - BM 15766: 2

Related Diseases

1.	Smith-Lemli-Opitz Syndrome 09/01/1997 - "To confirm that blocking 7-dehydrocholesterol delta 7 reductase (7DHC reductase), as observed in Smith-Lemli-Opitz syndrome (SLOS), induces craniofacial defects, we tested BM15.766, which blocks 7DHC reductase but is chemically unrelated to the holoprosencephaly-inducing teratogen AY9944. "
2.	Holoprosencephaly (Arhinencephaly) 09/01/1997 - "Cholesterol biosynthesis inhibited by BM15.766 induces holoprosencephaly in the rat." 09/01/1997 - "To confirm that blocking 7-dehydrocholesterol delta 7 reductase (7DHC reductase), as observed in Smith-Lemli-Opitz syndrome (SLOS), induces craniofacial defects, we tested BM15.766, which blocks 7DHC reductase but is chemically unrelated to the holoprosencephaly-inducing teratogen AY9944. "
3.	Animal Disease Models 06/01/1996 - "For the purpose of experimental teratology, an animal disease model consisting of the offspring of pregnant rats treated with AY 9944 or BM 15766, inhibitors of 7-dehydrocholesterol-delta 7-reductase, was established. "

Related Drugs and Biologics

1.	trans- 1,4- Bis(2- chlorobenzaminomethyl)cyclohexane Dihydrochloride
2.	Teratogens
3.	Oxidoreductases (Dehydrogenase)
4.	Cholesterol
5.	7-dehydrocholesterol reductase